Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
